Patents by Inventor Christophe Poitevin
Christophe Poitevin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230227429Abstract: This invention relates to compounds of formula (I) and salts, solvates, tautomers, N-oxides, stereoisomers, polymorphs and/or prodrugs thereof. Also disclosed is the use of the compounds of formula (I) to treat necroptosis and/or inhibit MLKL.Type: ApplicationFiled: June 18, 2021Publication date: July 20, 2023Inventors: Jean-Marc Daniel Garnier, Martin Brzozowski, John Thomas Feutrill, Guillaume Laurent Lessene, Christopher Gardner, Peter Edward Czabotar, Angus Cowan, Katherine Davies, Pooja Sharma, Carole Annie Schuster-Klein, Christophe Poitevin
-
Publication number: 20230227428Abstract: This invention relates to compounds of formula (I) and salts, solvates, tautomers, N-oxides, stereoisomers, polymorphs and/or prodrugs thereof. Also disclosed is the use of the compound of formula (I) to treat necroptosis and/or inhibit RIP1 and/or MLKL.Type: ApplicationFiled: June 21, 2021Publication date: July 20, 2023Inventors: Jean-Marc Daniel Garnier, Martin Brzozowski, John Thomas Feutrill, Guillaume Laurent Lessene, Christopher Gardner, Peter Edward Czabotar, Angus Cowan, Pooja Sharma, Carole Annie Schuster-Klein, Christophe Poitevin
-
Patent number: 9809553Abstract: A compound of formula (I): wherein the substituents are as defined in the description. Medicinal products containing the same which are useful in treating or preventing pathologies which are the result of activation of the RhoA/ROCK pathway and phosphorylation of the myosin light chain.Type: GrantFiled: February 20, 2015Date of Patent: November 7, 2017Assignee: LES LABORATOIRES SERVIERInventors: Stéfano Chimenti, Christine Courchay, Aimee Dessinges, Françoise Gellibert, Bertrand Goument, Marc Konnert, Jean-Louis Peglion, Christophe Poitevin, Jean-Paul Vilaine, Nicole Villeneuve
-
Publication number: 20170137385Abstract: A compound of formula (I): wherein the substituents are as defined in the description. Medicinal products containing the same which are useful in treating or preventing pathologies which are the result of activation of the RhoA/ROCK pathway and phosphorylation of the myosin light chain.Type: ApplicationFiled: February 20, 2015Publication date: May 18, 2017Inventors: Stéfano CHIMENTI, Christine COURCHAY, Aimee DESSINGES, Françoise GELLIBERT, Bertrand GOUMENT, Marc KONNERT, Jean-Louis PEGLION, Christophe POITEVIN, Jean-Paul VILAINE, Nicole VILLENEUVE
-
Patent number: 7470683Abstract: Compounds of formula I, of trans relative configuration: wherein: X represents an oxygen atom or an NR2 group, Y represents a group selected from —CH2—, —(CH2)2— and —CH?CH—, R1 and R2, which may be the same or different, each represents a hydrogen atom or a group selected from alkyl, cycloalkyl and cycloalkylalkyl, in racemic form or in the form of optical isomers, and also addition salts thereof with a pharmaceutically acceptable acid, and hydrates thereof. Medicinal products containing the same which are useful in the treatment of disorders of the central nervous system that involve the dopaminergic system.Type: GrantFiled: September 25, 2007Date of Patent: December 30, 2008Assignee: Les Laboratoires ServierInventors: Jean-Louis Peglion, Christophe Poitevin, Mark Millan, Mauricette Brocco
-
Publication number: 20080076765Abstract: Compounds of formula I, of trans relative configuration: wherein: X represents an oxygen atom or an NR2 group, Y represents a group selected from —CH2—, —(CH2)2— and —CH?CH—, R1 and R2, which may be the same or different, each represents a hydrogen atom or a group selected from alkyl, cycloalkyl and cycloalkylalkyl, in racemic form or in the form of optical isomers, and also addition salts thereof with a pharmaceutically acceptable acid, and hydrates thereof. Medicinal products containing the same which are useful in the treatment of disorders of the central nervous system that involve the dopaminergic system.Type: ApplicationFiled: September 25, 2007Publication date: March 27, 2008Applicant: LES LABORATOIRES SERVIERInventors: Jean-Louis Peglion, Christophe Poitevin, Mark Millan, Mauricette Brocco
-
Patent number: 6908922Abstract: Compound of formula (I): wherein: V represents a single bond or an alkylene chain, M represents a single bond or an alkylene chain, A and E each represents nitrogen or CH, but at least one of the two groups A or E represents nitrogen, W represents a group of formula (i), (ii) or (iii): Medicinal products containing the same which are useful in the treatment of diseases or pathological conditions ins which endothelial dysfunction is known.Type: GrantFiled: November 12, 2002Date of Patent: June 21, 2005Assignee: Les Laboratoires ServierInventors: Jean-Louis Peglion, Christophe Poitevin, Jean-Paul Vilaine, Nicole Villeneuve, Marie-Pierre Bourguignon, Catherine Thollon
-
Patent number: 6903103Abstract: Compound of formula (I): wherein: V represents a single bond or an alkylene chain, M represents a single bond or an alkylene chain, A and E each represents nitrogen or CH, but at least one of the two groups A or E represents nitrogen, W represents a group of formula (i), (ii) or (iii): wherein: X represents carbonyl, sulphonyl or sulphoxide, G1, G2 and G3 are as defined in the description, T represents a fused phenyl group or a fused pyridyl group, R1 represents hydrogen, linear or branched (C1-C6)alkyl, aryl or aryl-(C1-C6)alkyl in which the alkyl moiety is linear or branched, R2a and R2b, which are the same or different, are as defined in the description, R3 represents aryl or heteroaryl-A as defined in the description, each of which groups may optionally be substituted, Y represents aryloxy, heteroaryloxy or heteroaryl-B as defined in the description, each of which groups may optionally be substituted, its isomers, its hydrates, its solvates and addition salts thereof with a pharmaceutically aType: GrantFiled: February 20, 2003Date of Patent: June 7, 2005Assignee: Les Laboratories ServierInventors: Jean-Louis Peglion, Christophe Poitevin, Jean-Paul Vilaine, Nicole Villeneuve, Marie-Pierre Bourguignon, Catherine Thollon
-
Patent number: 6780868Abstract: Compounds of formula (I): wherein: V represents a single bond or a linear or branched (C1-C6)alkylene chain, M represents a single bond or a linear or branched (C1-C6)alkylene chain, A and E each represents nitrogen or CH, but at least one of the two groups A or E represents nitrogen, W represents a group of formula (i): X represents carbonyl, G1 represents a linear C3 alkylene chain optionally containing a double bond and/or being optionally substituted by a hydroxyl group, their isomers, their hydrates, their solvates, and additional salts thereof with a pharmaceutically acceptable acid, and medicinal products containing the same which are useful in the treatment of diseases or pathological conditions in which endothelial dysfunction is known.Type: GrantFiled: February 20, 2003Date of Patent: August 24, 2004Assignee: Les Laboratoires ServierInventors: Jean-Louis Peglion, Christophe Poitevin, Jean-Paul Vilaine, Nicole Villeneuve, Marie-Pierre Bourguignon, Catherine Thollon
-
Patent number: 6696469Abstract: Compounds of formula (I): wherein: X represents a heterocycle bonded to the remainder of the molecule by a nitrogen atom of the heterocycle, or an —NR2R3 group wherein R2 represents hydrogen or alkyl, and R3 represents aryl, 1,3 dihydro-2H-benzimidazolyl-2-one or alkyl substituted by a heterocycle, n represents zero or 1, R1 represents hydrogen or alkyl, Ra represents a single bond or an alkylene chain, A represents nitrogen or CH, E represents nitrogen or CRe, wherein Re is as defined in the description, Rb represents a single bond or an alkylene chain as defined in the description, W represents aryl or heteroaryl, Their optical isomers, and addition salts thereof with a pharmaceutically acceptable acid, and medicinal products containing the same which are useful for treatment of diseases or pathological conditions in which endothelial dysfunction is known.Type: GrantFiled: October 12, 2001Date of Patent: February 24, 2004Assignee: Les Laboratoires ServierInventors: Jean-Louis Peglion, Jean-Paul Vilaine, Nicole Villeneuve, Catherine Thollon, Marie-Pierre Bourguignon, Christophe Poitevin
-
Publication number: 20030229100Abstract: Compound of formula (I): 1Type: ApplicationFiled: February 20, 2003Publication date: December 11, 2003Inventors: Jean-Louis Peglion, Christophe Poitevin, Jean-Paul Vilaine, Nicole Villeneuve, Marie-Pierre Bourguignon, Catherine Thollon
-
Publication number: 20030225105Abstract: Compound of formula (I): 1Type: ApplicationFiled: February 20, 2003Publication date: December 4, 2003Inventors: Jean-Louis Peglion, Christophe Poitevin, Jean-Paul Vilaine, Nicole VIlleneuve, Marie-Pierre Bourguignon, Catherine Thollon
-
Publication number: 20030191132Abstract: Compound of formula (I): 1Type: ApplicationFiled: November 12, 2002Publication date: October 9, 2003Inventors: Jean-Louis Peglion, Christophe Poitevin, Jean-Paul Vilaine, Nicole Villeneuve, Marie-Pierre Bourguignon, Catherine Thollon
-
Patent number: 6566364Abstract: Compound of formula (I): wherein: V represents a single bond or an alkylene chain, M represents a single bond or an alkylene chain, A and E each represents nitrogen or CH, but at least one of the two groups A or E represents nitrogen, W represents a group of formula (i), (ii) or (iii): Medicinal products containing the same which are useful in the treatment of diseases or pathological conditions in which endothelial dysfunction is known.Type: GrantFiled: December 29, 2000Date of Patent: May 20, 2003Assignee: Les Laboratoires ServierInventors: Jean-Louis Peglion, Christophe Poitevin, Jean-Paul Vilaine, Nicole Villeneuve, Marie-Pierre Bourguignon, Catherine Thollon
-
Patent number: 6486171Abstract: A compound selected from those of formula (I): wherein: W represents optionally substituted naphthyl, or a group of formula Y (wherein) as defined in the description, n represents an integer from 1 to 6 inclusive, Z represents a single bond, oxygen, or optionally substituted nitrogen, A and Q each represent CH or nitrogen, it being understood that A or Q must be N and the other CH, M, together with a carbon of the phenyl to which it is bonded, represents thienyl, furyl, pyrrolyl, or oxopyrrolyl, its isomers, and pharmaceutically-acceptable acid or base addition salts thereof, and medicinal products containing the same, which are useful in the treatment of some CNS disorders.Type: GrantFiled: March 25, 2002Date of Patent: November 26, 2002Assignee: Les Laboratoires ServierInventors: Jean-Louis Peglion, Aimée Dessinges, Christophe Poitevin, Mark Millan, Anne Dekeyne
-
Publication number: 20020161228Abstract: A compound selected from those of formula (I): 1Type: ApplicationFiled: March 25, 2002Publication date: October 31, 2002Applicant: ADIR ET COMPAGNIEInventors: Jean Louis Peglion, Aimee Dessinges, Christophe Poitevin, Mark Millan, Anne Dekeyne
-
Patent number: 6399616Abstract: A compound selected from those of formula (I): wherein: W represents optionally substituted naphthyl, n represents an integer from 2 to 3 inclusive, Z represents a single bond, A represents nitrogen, Q represents nitrogen, M, together with the carbon of pyridyl to which it is bonded, represents thieno, furo, pyrrolo or oxopyrrolo, Its optical isomers and pharmaceutically-acceptable acid or base additional salts thereof, and Medicinal products containing the same which are useful in the treatment of CNS disorders. It being understood that “aryl” is phenyl, naphthyl, dihydronaphthyl, or tetrahydronaphthyl.Type: GrantFiled: August 18, 2000Date of Patent: June 4, 2002Assignee: Les Laboratoires ServierInventors: Jean-Louis Peglion, Aimée Dessinges, Christophe Poitevin, Mark Millan, Anne Dekeyne
-
Publication number: 20020065419Abstract: Compound of formula (I): 1Type: ApplicationFiled: October 12, 2001Publication date: May 30, 2002Inventors: Jean-Louis Peglion, Jean-Paul Vilaine, Nicole Villeneuve, Catherine Thollon, Marie-Pierre Bourguignon, Christophe Poitevin
-
Patent number: 6323217Abstract: A compound of formula (I): wherein: R1 represents hydrogen or alkyl, R2a and R2b represent a group selected from hydrogen, halogen, alkyl, hydroxy, alkoxy, trihaloalkyl, cyano, nitro, amino, alkylamino and dialkylamino, R3 represents hydrogen or hydroxy, X represents oxygen or methylene, V represents an alkylene chain that is optionally unsaturated and optionally substituted, U represents a bond or an alkylene chain, W represents a group selected from aryl and heteroaryl, each of those groups being optionally substituted by one or more identical or different groups, its isomers, its hydrates, its solvates and addition salts thereof with a pharmaceutically acceptable acid. Medicinal products containing the same which are useful in the treatment of diseases or pathological conditions in which endothelial dysfunction is known.Type: GrantFiled: January 30, 2001Date of Patent: November 27, 2001Assignee: Adir et CompagnieInventors: Jean-Louis Peglion, Aimée Dessinges, Christophe Poitevin, Jean-Paul Vilaine, Nicole Villeneuve, Catherine Thollon, Marie-Pierre Bourguignon
-
Publication number: 20010034352Abstract: Compound of formula (I): 1Type: ApplicationFiled: January 30, 2001Publication date: October 25, 2001Inventors: Jean-Louis Peglion, Aimee Dessinges, Christophe Poitevin, Jean-Paul Vilaine, Nicole Villeneuve, Catherine Thollon, Marie-Pierre Bourguignon